Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

William Waddill Biography and Net Worth

Director of Arrowhead Pharmaceuticals

Founder of Square One Finance and Square One Resources Ltd., William D. Waddill is on the board of Arrowhead Pharmaceuticals, Inc., Protagonist Pty Ltd., Annexon, Inc. and Protagonist Therapeutics, Inc. Mr. Waddill previously occupied the position of Senior Director-Finance & Administration at Exelixis, Inc., Chief Financial Officer for Medical Science Partners LP, Chief Financial Officer, Senior VP & Treasurer at Calithera Biosciences, Inc., Principal at Square One Finance, Chief Financial Officer, Treasurer & Senior VP of OncoMed Pharmaceuticals, Inc., Chief Financial Officer & Senior Vice President for Ilypsa, Inc., Principal at PricewaterhouseCoopers LLP, Principal at Deloitte & Touche, Inc. and Chairman at The Association of Bioscience Financial Officers.

He received an undergraduate degree from the University of Illinois.

What is William D. Waddill's net worth?: The estimated net worth of William D. Waddill is at least $224,520.00 as of September 10th, 2024. Mr. Waddill owns 12,000 shares of Arrowhead Pharmaceuticals stock worth more than $224,520 as of November 20th. This net worth approximation does not reflect any other assets that Mr. Waddill may own. Learn More about William D. Waddill's net worth.
How do I contact William D. Waddill?: The corporate mailing address for Mr. Waddill and other Arrowhead Pharmaceuticals executives is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. Arrowhead Pharmaceuticals can also be reached via phone at (626) 304-3400 and via email at [email protected]. Learn More on William D. Waddill's contact information.
Has William D. Waddill been buying or selling shares of Arrowhead Pharmaceuticals?: William D. Waddill has not been actively trading shares of Arrowhead Pharmaceuticals over the course of the past ninety days. Most recently, William D. Waddill sold 3,200 shares of the business's stock in a transaction on Monday, January 9th. The shares were sold at an average price of $30.00, for a transaction totalling $96,000.00. Following the completion of the sale, the director now directly owns 28,950 shares of the company's stock, valued at $868,500. Learn More on William D. Waddill's trading history.
Who are Arrowhead Pharmaceuticals' active insiders?: Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Javier San Martin (Insider), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Arrowhead Pharmaceuticals?: In the last year, Arrowhead Pharmaceuticals insiders bought shares 2 times. They purchased a total of 2,000 shares worth more than $54,990.00. In the last year, insiders at the biotechnology company sold shares 14 times. They sold a total of 247,332 shares worth more than $8,158,854.05. The most recent insider tranaction occured on July, 2nd when insider Tracie Oliver sold 9,394 shares worth more than $237,480.32. Insiders at Arrowhead Pharmaceuticals own 4.5% of the company. Learn More about insider trades at Arrowhead Pharmaceuticals.
Information on this page was last updated on 7/2/2024.

William D. Waddill Insider Trading History at Arrowhead Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/9/2023	Sell	3,200	$30.00	$96,000.00	28,950
1/3/2022	Sell	4,500	$64.72	$291,240.00
12/10/2020	Sell	3,000	$71.26	$213,780.00	26,800
1/11/2019	Sell	8,500	$14.77	$125,545.00	46,500

William D. Waddill Buying and Selling Activity at Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Company Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $18.71

$18.04

$18.75

50 Day Range

MA: $19.96

$17.70

$21.97

2 Week Range

Now: $18.71

$17.05

$39.83

Volume

792,142 shs

Average Volume

1,199,403 shs

Market Capitalization

$2.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share

From Darwin | Ad

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]